Protagonist Therapeutics Announces Initial Phase 2 Results with Hepcidin Mimetic PTG-300 in the Treatment of Polycythemia Vera

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 9/18/2026

1. XENE
2. SPY
3. HUBS
4. NUE
5. ONON
6. AAPL
7. TRMD
8. AZN
9. NVDA
10. USO

Go back to Protagonist Therapeutics Announces Initial Phase 2 Results with Hepcidin Mimetic PTG-300 in the Treatment of Polycythemia Vera
(NASDAQ: PTGX) Delayed: 143.39 -0.31 (0.22%)
Previous Close $143.70    52 Week High $24.52 
Open $143.09    52 Week Low $10.02 
Day High $143.65    P/E N/A 
Day Low $140.44    EPS $0.00 
Volume 143,888